A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; PD 325901 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms MErCuRIC1
- 10 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Results of initial dose escalation phase (n=25) in patients with advanced solid tumours, presented at the 41st European Society for Medical Oncology Congress.
- 07 Sep 2016 Status changed from completed to recruiting.